NEEDHAM, Mass., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common stock at the public offering price of $7.50 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $12.7 million, after deducting underwriting discounts and commissions. The closing of the option exercise is expected to occur on February 11, 2013, subject to customary closing conditions.
As previously announced, Celldex anticipates using the net proceeds from the offering, including the net proceeds from the exercise of the option to purchase additional shares, to fund Celldex's clinical trials of its product candidates and for working capital and other general corporate purposes.
Jefferies & Company, Inc. and Leerink Swann LLC acted as joint book-running managers of the offering. Oppenheimer & Co., Wedbush PacGrow Life Sciences, Brean Capital and Roth Capital Partners, LLC acted as co-managers of the offering.
A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. The final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525 or by email at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This announcement contains "forward-looking statements" such as those, among others, relating to Celldex's expectations regarding the completion and timing of the closing of the public offering and its anticipated use of net proceeds from the offering. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and Celldex cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the underwriters' option to purchase additional shares. There can be no assurance that Celldex will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Celldex and its business can be found in the "Risk Factors" section of Celldex's Form 10-K, filed with the SEC on March 8, 2012, and in the prospectus supplement and related prospectus relating to the proposed offering filed with the SEC on February 4, 2013. Celldex undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Celldex's expectations.
CONTACT: Sarah Cavanaugh Vice President of IR & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 email@example.com